NICE announced on 25 March 2014 that it is not recommending ZALTRAP® (aflibercept) to the NHS in England and Wales for the treatment of advanced, metastatic colorectal cancer (mCRC).1 Based on the same basic evidence, aflibercept was approved for use in Scotland on 10 March.2 Dr Rob Glynne-Jones, Consultant Clinical Oncologist, Macmillan Lead Clinician in Gastro-Intestinal Cancer, Northwood commented:"This is another example of NICE failing cancer patients who are in dire need of innovative medicines.
More...
More...